RECRUITINGINTERVENTIONAL
The SAFE Prospective Registry
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
About This Trial
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Who May Be Eligible (Plain English)
Who May Qualify:
- Atrial fibrillation (Afib); (paroxysmal, persistent)
- Patients indicated for catheter ablation and/or electrical cardioversion
- Signed willing to sign a consent form
Who Should NOT Join This Trial:
- Longstanding or permanent atrial fibrillation
- Severe mitral regurgitation
- Heart failure with a permanently reduced ejection fraction
- Cerebral ischaemic stroke in \< 3 months
- Severe kidney injury
- Severe renal insufficiency
- Hepatic insufficiency limiting biomarker sampling
- Myocardial infarction \< 3 months
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Atrial fibrillation (Afib); (paroxysmal, persistent)
* Patients indicated for catheter ablation and/or electrical cardioversion
* Signed informed consent
Exclusion Criteria:
* Longstanding or permanent atrial fibrillation
* Severe mitral regurgitation
* Heart failure with a permanently reduced ejection fraction
* Cerebral ischaemic stroke in \< 3 months
* Severe kidney injury
* Severe renal insufficiency
* Hepatic insufficiency limiting biomarker sampling
* Myocardial infarction \< 3 months
Treatments Being Tested
PROCEDURE
Catheter ablation and/or electrical cardioversion
Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Locations (1)
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia